Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 in Advanced or Metastatic Solid Tumors (Phase I/II, Monotherapy)
CTR20201888Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Sep 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in Nonhematologic neoplasms, sponsored by Akeso, Inc.. Started Sep 2020; status: completed.
02
Drugs
ivonescimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20201888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201888.